Fig. 3

Impaired glucose tolerance and decreased insulin secretion in aP2-CETPTg mice in vivo and in vitro. a IPGTT was performed in 10–12 week-old mice by intraperitoneal injecting D-glucose (1 g/kg body weight). Blood glucose levels were measured at 0, 15, 30, 60 and 120 min during IPGTT. n = 6 per group. Area under curve is calculated and showed (right). The aP2-CETPTg mice have impaired glucose tolerance than WT mice. b IPITT was performed in 10–12 week-old mice by intraperitoneal injecting insulin (0.75 IU/kg body weight). Blood glucose were recorded at 0, 15, 30, 60 and 120 min during IPITT. n = 6 per group. Area under curve is calculated and showed (right). The insulin sensitivity is increased in the NFR-CETPTg and aP2-CETPTg mice. c Plasma fasting insulin levels in NFR-CETPTg, aP2-CETPTg and WT mice. CETP transgenic mice exhibited decreased fasting insulin secretion than WT mice. n = 5 per group. d Plasma insulin levels were measured at 0, 15, 30 and 60 min during IPGTT in WT and aP2-CETPTg mice. After glucose challenge, aP2-CETPTg mice secreted less insulin than WT mice. n = 6 per group. e Insulin secretion ability was measured from isolated islets by glucose-stimulated insulin secretion. Eight islets per well, eight wells per group. Insulin release in response to 16.7 mmol/l glucose was significantly impaired in aP2-CETPTg mice compared with WT mice. Values are expressed as mean ± SD. *p < 0.05 compared with control group, **p < 0.01 compared with control group. IPGTT intraperitoneal glucose tolerance test, IPITT intraperitoneal insulin tolerance test